Drugs / GSK3174998
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03447314 | Mar 2018 → Jul 2020 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02723955 | Jun 2016 → Jul 2023 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02528357 | Sep 2015 → Apr 2020 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06160609 | Oct 2019 → Jan 2023 | refractory plasma cell neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1/2 | NCT04126200 | Oct 2019 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3174998 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02528357 ↗ |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 4 agonist” CHEMBL4297968 ↗1“OX40 agonist” PMID 36927527 ↗ Mar 2023 |
| Modality | Monoclonal antibody | “the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998” PMID 36927527 ↗ Mar 2023 |
| Route | Intravenous | “to be given as IV infusion for 30 minutes (min), Q3W” NCT02528357 ↗ |
| Target | TNFRSF4 | “Tumor necrosis factor receptor superfamily member 4 agonist” CHEMBL4297968 ↗ |